Syndax Pharmaceuticals Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Syndax Pharmaceuticals Inc. on February 24, 2022, covering events occurring on February 22, 2022. The company is a Delaware corporation with its principal executive offices in Waltham, Massachusetts, and its common stock trades on The Nasdaq Stock Market under the symbol "SNDX."
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on corporate governance changes.
Material Changes
The primary material change reported is the departure of a director:
- Resignation: Fabrice Egros, PharmD, Ph.D., resigned from the Board of Directors effective February 23, 2022.
- Reason: The resignation is due to an increase in the scope of Dr. Egros's role at Lupin Limited.
- Disagreement: The filing explicitly states the resignation is not due to any disagreement with the Company regarding operations, policies, or practices.
- Board Action: Following the resignation, the Board appointed Dennis G. Podlesak as a member of the Audit Committee.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the standard disclosure regarding the director's departure.
Key Facts for Investor Verification
- Confirm the effective date of Fabrice Egros's resignation (February 23, 2022).
- Verify the appointment of Dennis G. Podlesak to the Audit Committee.
- Note that the departure is attributed to external professional commitments at Lupin Limited rather than internal company issues.